<table border="single" id="id_d7d010af-0029-4a70-9d34-9b013f503afd" width="357" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption id="id_5a395a51-13c1-4622-b6b2-41da2dca41ae">Table 13. Established and Other Potentially Significant Drug Interactions</caption>
<col width="38.1%"></col>
<col width="26.6%"></col>
<col width="35.3%"></col>
<tbody>
<tr id="id_ebe0b5ee-229f-44fd-9f02-ef7213583df3">
<td align="center" stylecode="Botrule Toprule Rrule Lrule" valign="top">Concomitant Drug</td>
<td align="center" stylecode="Botrule Rrule" valign="top">Effect on Concentration of Lamotrigine or Concomitant Drug</td>
<td align="center" stylecode="Botrule Rrule" valign="top">Clinical Comment</td>
</tr>
<tr id="id_fedf5ec6-638e-4ef3-8f51-11067f35dde7">
<td align="left" rowspan="2" stylecode="Lrule Botrule Rrule" valign="top">Estrogen-containing oral contraceptive preparations containing 30 mcg ethinylestradiol and 150 mcg levonorgestrel</td>
<td align="left" stylecode="Botrule Rrule" valign="top">
<paragraph>↓ lamotrigine </paragraph>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Decreased lamotrigine levels approximately 50%. </td>
</tr>
<tr id="id_1a1ea8c7-cbb5-491e-a4ae-aa3107c6aac3">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">↓ levonorgestrel</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Decrease in levonorgestrel component by 19%.</td>
</tr>
<tr id="id_da5409c2-3683-4c05-beeb-9d08c1f652f3">
<td align="left" rowspan="2" stylecode="Lrule Botrule Rrule" valign="top">Carbamazepine (CBZ) and CBZ epoxide</td>
<td align="left" stylecode="Botrule Rrule" valign="top">
<paragraph>↓ lamotrigine </paragraph>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Addition of carbamazepine decreases lamotrigine concentration approximately 40%. </td>
</tr>
<tr id="id_f3eaa628-4e3e-4d2e-bdf1-5d9ce86ed490">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">? CBZ epoxide</td>
<td align="left" stylecode="Botrule Rrule" valign="top">May increase CBZ epoxide levels. </td>
</tr>
<tr id="id_0e47fadd-08bc-42b2-8272-931828018427">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">Phenobarbital/Primidone </td>
<td align="left" stylecode="Botrule Rrule" valign="top">↓ lamotrigine </td>
<td align="left" stylecode="Botrule Rrule" valign="top">Decreased lamotrigine concentration approximately 40%. </td>
</tr>
<tr id="id_5c7d930f-8979-4b4e-9fcd-e7cfcf67d5d9">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">Phenytoin (PHT) </td>
<td align="left" stylecode="Botrule Rrule" valign="top">↓ lamotrigine </td>
<td align="left" stylecode="Botrule Rrule" valign="top">Decreased lamotrigine concentration approximately 40%. </td>
</tr>
<tr id="id_2eb8b80a-8432-4c5a-9299-9c5b03a08647">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">Rifampin </td>
<td align="left" stylecode="Botrule Rrule" valign="top">↓ lamotrigine </td>
<td align="left" stylecode="Botrule Rrule" valign="top">Decreased lamotrigine AUC approximately 40%. </td>
</tr>
<tr id="id_733ea4b5-bd9e-4f4f-88a0-f663185a95ee">
<td align="left" rowspan="2" stylecode="Lrule Botrule Rrule" valign="top">Valproate </td>
<td align="left" stylecode="Botrule Rrule" valign="top">
<paragraph>↑ lamotrigine </paragraph>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Increased lamotrigine concentrations slightly more than 2 fold. </td>
</tr>
<tr id="id_d429ed31-68e4-4f3a-89be-b796fba3e9b7">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">? valproate </td>
<td align="left" stylecode="Botrule Rrule" valign="top">Decreased valproate concentrations an average of 25% over a 3 week period then stabilized in healthy volunteers; no change in controlled clinical trials in epilepsy patients. </td>
</tr>
</tbody>
</table>